Stanford Head and Neck Center

Head and Neck Oncology Program (HNOP)

Make an Appointment

(650) 498-6000

Studies and Clinical Trials

Current Open Studies

*  studies in red are Stanford investigator initiated

Minimally Invasive Surgery

Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-dose or Standard-dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer (ECOG E3311)

Chemotherapy, Radiation Therapy, and Chemoirradiation

  • A Phase II Study of Sequential and Concurrent Chemoradiation for Patients with Advanced Nasopharyngeal Carcinoma (NPC) (ENT0025)

  • Phase I Trial of Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers (ENT0031)

  • A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer (ECOGE1305)
  • A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors (RTOG1008)
  • Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck (RTOG1216) 

Targeted and Immune Based Treatment

  • A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MPDL3280A (anti-PDL-1 monoclonal antibody) Administered Intravenously as a Single Agent to Patients with Locally Advanced or Metastatic Solid Tumors (VAR0082)
  • A Phase 1 Study of Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors: Melanoma, Renal Cell, Non-Small Cell Lung and Head and Neck Cancer (VAR0093)

Palliative Treatment

Weekly Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients with SCCHN (ENT0033)